By Peiwen Sun · Cosmetics R&D & Innovation · Published 08 Apr 2026
A recombinant collagen fragment engineered by AI-assisted protein screening has just reached commercial availability, and it is worth understanding even if your brand never touches it directly — because it signals where large ingredient suppliers are pointing their R&D budgets. SkinNexus™ Collag3n, developed jointly by BASF Care Chemicals and biomanufacturing partner Bota Biosciences, is a yeast-fermented Collagen III fragment built to match the human amino-acid sequence exactly, rather than approximate it the way conventional hydrolysed collagen peptides do.
For OEM and ODM buyers sourcing anti-aging actives, the story here is less about one ingredient and more about a shift in how those ingredients get made. Screening thousands of candidate sequences computationally before a single one reaches the bench is a materially different discovery process than the trial-and-error extraction methods that have defined the collagen category for decades. This guide walks through what SkinNexus Collag3n actually is, the data behind it, how it compares with traditional collagen actives, and what formulators evaluating it should ask their supplier before committing.
Key takeaways
- SkinNexus™ Collag3n is a recombinant, vegan Collagen III fragment produced by engineered yeast fermentation, designed to be 100% identical to the human amino-acid sequence.
- BASF and Bota Biosciences screened more than 2,000 candidate collagen fragments using Bota’s “Physical AI” Saion platform before selecting this sequence for commercial development.
- In 3D dermis-model testing it raised Collagen I by 48%, Collagen III by 82% and Collagen V by 71%; a 4-week clinical study on women aged 53–70 reported improved sagging and wrinkle appearance.
- It launched alongside a companion peptide, NeoHelix™ Regenerate, targeting the same collagen-renewal pathway.
- BASF is positioning the ingredient as a more cost-accessible entry point into “collagen banking” claims, a category that has previously skewed toward premium pricing.
What SkinNexus Collag3n actually is
SkinNexus™ Collag3n is a recombinant Collagen III protein fragment produced through engineered yeast fermentation rather than extraction from animal or marine tissue, which makes the finished ingredient fully vegan. Its defining claim is sequence fidelity: BASF states the amino-acid chain is 100% identical to human Collagen III, the collagen subtype most closely tied to skin elasticity and the dermal matrix that visibly thins with age.
This distinguishes it from conventional collagen peptides, which are typically hydrolysed fragments of animal- or marine-derived collagen with sequences that only approximate human collagen. A precisely matched sequence is the basis for BASF’s biomimetic positioning, and it is the reason the ingredient sits in the “collagen banking” conversation rather than the older “collagen replacement” framing.
The AI-assisted discovery process behind it
The ingredient is the first commercial result of a partnership between BASF’s Care Chemicals division and Bota Biosciences, a biomanufacturing company whose Saion platform combines machine-learning candidate screening with automated wet-lab experimentation — what the companies describe as “Physical AI.” Rather than testing sequences one at a time, the platform ran efficacy screening and industrial feasibility checks in parallel across thousands of candidates simultaneously.
BASF reports that more than 2,000 collagen fragment variants were screened before this specific sequence was selected for development. For OEM buyers, the practical takeaway is less about the technology story and more about consistency: an ingredient selected this systematically for both biological performance and manufacturability tends to arrive with tighter batch-to-batch specifications than earlier-generation actives discovered through slower, sequential R&D.
Clinical and efficacy data
BASF’s published testing programme covers two stages. In 3D reconstructed dermis models, SkinNexus Collag3n increased Collagen I synthesis by 48%, Collagen III by 82% and Collagen V by 71% — a broader remodeling signal than a Collagen-III-only ingredient name might suggest, since it appears to influence the wider collagen network rather than a single subtype in isolation.
In a 4-week clinical study on women aged 53 to 70, the ingredient was associated with improved sagging and reduced wrinkle appearance, with BASF reporting that it outperformed a benchmark collagen ingredient used at ten times the concentration. As with any supplier-reported clinical data, formulators should request the full study protocol and statistical detail directly from BASF rather than relying on summary claims alone.
How it differs from traditional collagen peptides
Most collagen ingredients on the market are hydrolysed peptides: animal or marine collagen broken down into smaller fragments through acid or enzymatic treatment. These vary in sequence, molecular weight and purity depending on the source material and processing method, and none are an exact match to human collagen.
SkinNexus Collag3n’s recombinant production route sidesteps that variability by engineering the target sequence directly rather than deriving it from a biological source and hoping the resulting fragments land close to human collagen. That also removes the animal-sourcing question entirely, since the protein is fermented rather than extracted, which is relevant for brands building vegan or cruelty-free claims around collagen-support products.
Companion launch: NeoHelix Regenerate
BASF released SkinNexus Collag3n alongside a second, complementary active called NeoHelix™ Regenerate, a precision peptide aimed at the same collagen-renewal pathway. Launching as a pair rather than a single SKU suggests BASF is building toward a platform of collagen-support actives that can be combined within a routine, rather than treating this as a one-off ingredient release.
For brands and OEM partners planning multi-step anti-aging ranges, this is worth tracking: a supplier that pairs actives at launch is signaling how it expects formulators to use them together, which can shape how a serum-plus-cream or serum-plus-booster routine gets structured around a single ingredient story.
Formulation considerations
BASF has not published a full public technical data sheet with exact dosage and pH windows at the time of writing, so formulators evaluating this ingredient should request the official documentation and safety data directly from BASF Care Chemicals. That said, recombinant protein actives of this general class share some predictable handling characteristics.
They are water-soluble and typically added to the aqueous phase during the cool-down step of manufacture, to avoid denaturing the protein structure under heat. Use levels tend to sit in the low, protein-typical range — commonly a fraction of a percent to a few percent depending on the specific grade — and formulators should always confirm the supplier’s recommended dosing rather than assuming a category norm. Compatibility with strong oxidizers, extreme pH and certain preservative systems should be screened in the target base, as with any protein or peptide ingredient.
Vegan positioning and sourcing transparency
Because the ingredient is produced entirely by yeast fermentation, it carries a straightforward vegan claim without the sourcing caveats that sometimes accompany “vegan-friendly” collagen alternatives derived from plant extracts that merely support the skin’s own collagen production. This is a meaningfully different claim from marketing collagen-boosting botanicals, and brands should be precise about which category their product falls into when writing pack copy.
OEM buyers should also request INCI documentation and any available substantiation for “AI-designed” or “human-identical” language before using it in marketing, since regulators in several markets scrutinize biotechnology and precision-engineering claims more closely than conventional ingredient descriptions.
Market positioning and the collagen-banking trend
BASF is explicitly pitching SkinNexus Collag3n as a cost-accessible alternative in a collagen-active category that has skewed toward premium price points. If that positioning holds through commercial pricing, it could open collagen-banking claims — the idea of supporting collagen levels preventively, before visible loss occurs, rather than only correcting sagging after the fact — to a wider range of price tiers than has typically carried this kind of ingredient story.
That matters for OEM manufacturers serving mass-premium and mid-tier brands, which have historically been priced out of “hero collagen active” formulations built around costlier ingredients. Whether the accessible pricing materializes at the finished-product level will depend on minimum order quantities and per-kilogram costs that BASF has not yet made public.
Suitable product formats
Based on how this class of recombinant collagen active is typically formulated, suitable product formats include anti-aging serums and ampoules, night creams, eye contour treatments, and sheet-mask or booster formats built around a hero collagen claim. Its water-soluble nature makes it straightforward to incorporate into lightweight, fast-absorbing textures that consumers associate with “active” serums rather than heavier occlusive creams.
Brands considering it for a booster or ampoule format should factor in shelf-life and stability testing specific to protein actives, since proteins can be more sensitive to long-term storage conditions than smaller-molecule actives commonly used in the same product categories.
Sourcing considerations for OEM and private-label buyers
Any brand considering this ingredient for a private-label launch should work through their contract manufacturer to confirm current availability, minimum order quantities and lead times directly with BASF Care Chemicals, since newly launched actives sometimes carry longer allocation queues than established ingredients. It is also worth asking your OEM partner whether they have prior formulation experience with recombinant protein actives specifically, since handling requirements differ from standard peptide or botanical extracts. Buyers researching how OEM sourcing decisions like this fit into a broader private-label development process may find our ingredients & formulations guides useful background before briefing a manufacturer.
For brands newer to how contract manufacturing relationships work in general — including how ingredient selection interacts with MOQ and product briefs — our explainer on what OEM manufacturing involves is a useful starting point before approaching a supplier about a specific active like this one.
Frequently asked questions
Is SkinNexus Collag3n vegan?
Yes. It is produced through yeast fermentation rather than extracted from animal or marine collagen sources, so it carries a straightforward vegan claim.
How is it different from marine or bovine collagen peptides?
Traditional collagen peptides are hydrolysed from animal or marine sources and vary in sequence depending on the source material. SkinNexus Collag3n is engineered to match the human Collagen III sequence directly, which BASF frames as a more targeted, biomimetic approach than extraction-based peptides.
Is it available for brands to formulate with now?
BASF and Bota Biosciences announced the commercial launch on 30 June 2026, following a debut at in-cosmetics Global earlier in the year. Brands and OEM partners should contact BASF Care Chemicals directly for samples, technical documentation and current lead times.
What product types is it best suited for?
Based on its water-soluble, protein-based profile, it fits anti-aging serums, ampoules, night creams, eye contour treatments and booster or sheet-mask formats built around a collagen-support claim.
This article is an independent market-insight summary based on publicly available supplier statements and industry trade press. Formulators should confirm current specifications, use levels and regulatory status directly with the supplier before use.
About the author
Peiwen Sun is a China-based cosmetics R&D and innovation executive with senior-level experience in beauty product research, formulation and innovation management. Her work focuses on translating cosmetic science and emerging technologies into commercially relevant beauty products. LinkedIn
